A waterproof, gel-free ECG patch developed at RMIT University is being tested in a clinical trial in Perth, as Australian startup Lubdub assesses whether it can provide detailed heart rhythm data comparable to that from a medical-grade Holter monitor.
The trial began this week at Midlands Medical Specialists in Western Australia. Patients already prescribed a Holter monitor will also wear Lubdub’s prototype patch, which the company says can continuously track heart rhythm for up to 14 days during everyday activities.
RMIT Professor and Lubdub co-founder Sharath Sriram said earlier tests with healthy volunteers found the patch comfortable and produced promising results. “The flexible sensors make better contact with the skin than those used in traditional Holter monitors,” he said. RMIT says the patch’s data was 18 times cleaner than readings from traditional Holter monitors.
Sriram said reducing the work involved in producing cardiac reports could allow the same workforce to monitor up to 85 percent more patients, even before tools such as AI are added. The trial is intended to gather evidence for further development and possible regulatory approval.
Lubdub plans to combine the ECG patch with biomarker technologies testing and wearable ultrasound imaging in a single software platform. The patch is the first of the three heart-monitoring technologies the company plans to bring together. RMIT recently licensed the intellectual property for the ECG and biomarker to Lubdub.
Sriram said early heart disease symptoms are often missed, despite cardiovascular disease accounting for a third of deaths globally and nearly a quarter in Australia. “Our innovation is about simpler and more effective screening, because prevention is better than cure,” he said.
The Heart Foundation selected Lubdub as one of its 10 most promising heart health projects for 2026. In September, the company announced an oversubscribed $6 million seed funding round, twice its original $3 million target, backed mainly by physicians and heart specialists.
Lubdub co-founder and director Nikhilesh Bappoo said his interest in making testing more accessible was shaped by his father’s heart attack in Perth and timely specialist care. He thought about the more limited access in Mauritius, where he grew up. “Had it happened there, the outcome could have been very different,” he said.
